Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.6B CNY |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
116.2B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
70.3B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
69.8B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
52.8B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
33.8B AUD |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
63.1B CNY |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.3B USD |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
65.8B HKD |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
|
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
7.1B USD |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Shanghai Pharmaceuticals Holding Co Ltd is 10.4%, which is below its 3-year median of 11.4%.
Over the last 3 years, Shanghai Pharmaceuticals Holding Co Ltd’s Gross Margin has decreased from 12.5% to 10.4%. During this period, it reached a low of 10.3% on Jun 30, 2025 and a high of 13.1% on Dec 31, 2022.